NCT07234656 Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer
| NCT ID | NCT07234656 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigitta Rasmussen Villumsen |
| Condition | Fear of Cancer Recurrence |
| Study Type | OBSERVATIONAL |
| Enrollment | 105 participants |
| Start Date | 2025-09-30 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 105 participants in total. It began in 2025-09-30 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to gather real-world information about Fear of Cancer Recurrence (FCR) following surgery in patients with renal cell carcinoma (RCC) and their partners/spouses by 1) establishing a panel consisting of patients with or without partners/spouses to facilitate patient-partnered research. Furthermore, 2) Through discussions among panel members and researchers identification of the most pertinent topics related to FCR, as well as the optimal timing and methods for collecting that information in the follow-up care after surgery. Finally, to conduct a feasibility and pilot study to investigate the feasibility of the recommendations developed in 1) + 2) and assess FCR in patients with RCC following surgery and their partners/spouses. In phase 1 participants (panel members) will be asked to collaborate with researchers in the development of recommendations for FCR questions, mode of administration and timing in the follow-up care after surgically treated kidney cancer. In phase 2 participants (patients and partners) in follow-up care after surgically treated kidney cancer are asked to answer questions about FCR at specific timepoints defined by panel members and researchers in phase 1.
Eligibility Criteria
Inclusion Criteria: Phase 1: * Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse * Partner/spouse to patients who fullfil the inclusion criteria * Patients have undergone surgery due to localized RCC (T1-T2-T3 tumor) * Time since surgery: 0-120 months * Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish * Patients/partners/spouses able to and willing to attend online project meetings or in person at Gødstrup Hospital. Phase 2: * Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse * Partner/spouse to patients who fullfill the inclusion criteria * Patients who have undergone surgery due to localized RCC (T1-T2-T3 tumor) * Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish * Able to receive digital communication from the hospital * Informed consent must be signed before answering Fear of Cancer Recurrence questions Exclusion Criteria: Both phases, both patients and partners/spouses: * Diagnosed with cognitive impairment * Untreated psychiatric disorders due to non-compliance Phase 2: • Patients and partners/spouses who were panelists in phase 1
Contact & Investigator
Brigitta R Villumsen, PhD
STUDY CHAIR
Gødstrup Hospital
Frequently Asked Questions
Who can join the NCT07234656 clinical trial?
This trial is open to participants of all sexes, studying Fear of Cancer Recurrence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07234656 currently recruiting?
Yes, NCT07234656 is actively recruiting participants. Contact the research team at brigvill@rm.dk for enrollment information.
Where is the NCT07234656 trial being conducted?
This trial is being conducted at Aalborg, Denmark, Aarhus, Denmark, Herning, Denmark.
Who is sponsoring the NCT07234656 clinical trial?
NCT07234656 is sponsored by Brigitta Rasmussen Villumsen. The principal investigator is Brigitta R Villumsen, PhD at Gødstrup Hospital. The trial plans to enroll 105 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.